Mixed Chimerism-Based Regimens in VCA

被引:0
|
作者
Lellouch A.G. [1 ,2 ]
Ng Z.Y. [1 ,2 ]
Kurtz J.M. [2 ,3 ]
Cetrulo C.L., Jr. [1 ,2 ]
机构
[1] Division of Plastic and Reconstructive Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA
[2] Vascularized Composite Allotransplantation Laboratory, Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA
[3] Department of Biology, Emmanuel College, Boston, MA
关键词
Bone marrow; Mixed chimerism; Transplant tolerance; Vascularized composite allograft;
D O I
10.1007/s40472-016-0124-7
中图分类号
学科分类号
摘要
Amputations and devastating injuries throughout the body can now be reconstructed by transplanting vascularized composite allografts (VCAs) of the extremities, face, penis, scalp, skull, abdominal wall, and even the uterus. While functional and quality of life outcomes have been highly promising, the requirement for, and complications from long-term immunosuppression have predictably been reported in VCA recipients as with solid organ transplantation. Immunologic tolerance represents an alternative strategy to prevent rejection of VCAs without the need for immunosuppression. Clinically, long-term tolerance of allografts without maintenance immunosuppression has been achieved in kidney transplantation patients through the induction of mixed chimerism, whereby both donor and recipient-derived lymphohematopoietic elements co-exist within the recipient. This paper serves to review the currently available evidence from both clinical and experimental studies on mixed chimerism based regimens in VCA. © 2016, Springer International Publishing AG.
引用
收藏
页码:390 / 394
页数:4
相关论文
共 50 条
  • [21] Mixed haematopoietic chimerism: how the initial dynamics of mixed chimerism correlate with later chimerism status
    Assing, K.
    Heilmann, C.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S379 - S380
  • [22] Introduction: Mixed chimerism
    Blume, KG
    BLOOD, 1999, 94 (10) : 78 - 79
  • [23] INCIDENCE OF MIXED CHIMERISM USING BUSULFAN CYCLOPHOSPHAMIDE CONTAINING REGIMENS IN ALLOGENEIC BONE-MARROW TRANSPLANTATION
    FISHLEDER, AJ
    BOLWELL, B
    LICHTIN, AE
    BONE MARROW TRANSPLANTATION, 1992, 9 (04) : 293 - 297
  • [24] Risk factors for mixed chimerism after stem cell transplantation with treosulfan or melphalan based conditioning regimens in children and adolescents with primary hemophagocytic lymphohistocytosis
    Wustrau, Katharina
    Albert, Michael H.
    Bader, Peter
    Beier, Rita
    Burkhardt, Birgit
    Chada, Martin
    Greil, Johann
    Gruhn, Bernd
    Kuehl, Joern-Sven
    Lang, Peter
    Meisel, Roland
    Schulz, Ansgar
    Seidel, Markus
    Speckmann, Carsten
    Sykora, Karl-Walter
    Wawer, Angela
    Woessmann, Wilhelm
    Ozga, Ann-Kathrin
    Ehl, Stephan
    Mueller, Ingo
    Lehmberg, Kai
    BONE MARROW TRANSPLANTATION, 2018, 53 : 86 - 87
  • [25] Mixed chimerism and transplant tolerance
    Sykes, M
    IMMUNITY, 2001, 14 (04) : 417 - 424
  • [26] Mixed chimerism and transplantation tolerance
    Cosimi, AB
    Sachs, DH
    TRANSPLANTATION, 2004, 77 (06) : 943 - 946
  • [27] Mixed chimerism and transplantation tolerance
    Wekerle, T
    Sykes, M
    ANNUAL REVIEW OF MEDICINE, 2001, 52 : 353 - +
  • [28] The Utility Of Monitoring Chimerism: More Predictive For Nonablative Regimens?
    Runaas, Lyndsey
    Longo, Walter L.
    Juckett, Mark
    Borcherding, Wayne
    Hematti, Peiman
    Cook, Rachel J.
    BLOOD, 2013, 122 (21)
  • [29] Absent mRNA accumulation of Th1 or Th2 cytokines in heart allografts with chimerism-based drug-induced tolerance
    Tomita, Y
    Zhang, QW
    Matsuzaki, G
    Shimizu, I
    Iwai, T
    Okano, S
    Nomoto, K
    Yasui, H
    SURGERY TODAY, 2005, 35 (05) : 364 - 370
  • [30] Clinical applications of mixed chimerism
    Exner, BG
    Domenick, MA
    Bergheim, M
    Mueller, WM
    Ildstad, ST
    HEMATOPOIETIC STEM CELLS: BIOLOGY AND TRANSPLANTATION, 1999, 872 : 377 - 386